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Abstract. Polyserase-1/TMPRSS9 is a type II transmembrane 
serine protease showing a complex molecular architecture 
characterized by the presence of three tandem serine protease 
domains in its amino acid sequence. This protease is widely 
expressed in mouse and human tissues, however, its functional 
significance is unknown in both normal and pathological 
conditions. In the present study, we evaluated the possible 
role of polyserase-1 in cancer progression. First, we showed 
that polyserase-1 increased the invasive capacities of PANC-1 
and SK-PC-3 pancreatic cancer cells. Moreover, the presence 
of polyserase-1 enhanced anchorage-independent growth 
and diminished the adhesion capability of PANC-1 cells to 
different extracellular matrix components. These effects were 
mediated by the efficient conversion of pro-uPA to active 
uPA and high phosphorylation levels of ERK detected in the 
PANC-1 cells expressing exogenous polyserase-1. Collectively, 
our data suggest that polyserase-1 may be involved in cancer 
progression and, similarly to what has been proposed for the 
closely related serine proteases matriptase and TMPRSS4, 
inhibition of TMPRSS9 activity may contribute to the inhibi-
tion of tumor growth.
Introduction
The tightly controlled proteolytic turnover of extracellular 
matrix (ECM) components in the immediate vicinity of the 
cell has a significant influence in the development and main-
tenance of tissue homeostasis (1). Proteolytic events within 
this pericellular microenvironment are mainly executed by 
extracellular or cell-surface metalloproteases and serine 
proteases (2). Among them, the type II transmembrane serine 
proteases (TTSPs), are membrane-anchored serine proteases 
involved in relevant biological functions (3). Thus, entero-
peptidase is produced by the duodenum and its function is 
essential to digest food efficiently (4). Corin contributes to 
blood pressure control through activation of atrial natriuretic 
peptide (5). Matriptase-2 participates in iron homeostasis (6), 
and hepsin is implicated in the process of hearing (7). These 
and other examples (8) illustrate the relevance of TTSPs in 
normal physiological processes.
The activities of the TTSPs also underlie different human 
disorders, including cancer. In fact, these proteases can cause 
an active pericellular degradation to breach tissue barriers 
thereby facilitating invasion of surrounding tissues (9). 
Moreover, this pericellular proteolysis may also trigger the 
activation of growth factors that promote tumor cell prolif-
eration and migration (10). However, TTSPs can also display 
antitumor effects. For instance, HPN, the gene encoding for 
human hepsin, is one of the most highly upregulated in prostate 
cancer, and this enzyme is exclusively detected in the surface 
of prostate carcinoma cells (11). In contrast, low expression 
levels of hepsin correlate with shorter patient survival in hepa-
tocellular carcinoma (12). Similarly, expression of matriptase 
was found to be markedly upregulated in different tumors of 
epithelial origin, including breast, lung or pancreatic carci-
nomas (13). However, a significant decrease in its expression 
was found in gastrointestinal tumors (14). DESC1 serine 
protease exhibits reduced expression levels in head and neck 
carcinomas in comparison with matched normal tissues (15), 
while its exogenous expression confers pro-tumor effects to 
MDCK cells and it was found to be upregulated in kidney, 
liver, breast and brain tumors (16). Additionally, different 
studies have highlighted the functions of different TTSPs as 
regulators of cellular signaling pathways and revealed the 
biochemical mechanisms underlying their pro-tumor or anti-
tumor effects (9).
Despite the increased understanding of the functional 
relevance of TTSPs, some members of this family have been 
characterized at the structural level while their roles in normal 
or pathological processes remain unknown. This is the case of 
polyserase-1 or transmembrane protease, serine 9 (TMPRSS9), 
a TTPS widely distributed in human and mouse tissues (17,18). 
Structurally, this enzyme shows a complex molecular archi-
tecture containing three tandem serine-protease domains 
called serase-1, serase-2 and serase-3 (17). The third domain 
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is predicted as catalytically inactive due to the presence of 
an alanine residue instead of the serine residue present in the 
active site of this type of enzyme. Serase-1B is a splice variant 
of TMPRSS9 containing only one serase domain which 
efficiently activates pro-uPA (18). Active uPA converts plas-
minogen to plasmin, an enzyme that cleaves different ECM 
components and activates latent collagenases. These effects 
contribute to the invasiveness of tumor cells of different 
origin, including pancreatic carcinomas. In fact, uPA exhibits 
marked overexpression in this type of tumor, and its detection 
provides prognostic information (19). Different reports have 
emphasized the pro-tumor activities of different TTSPs in 
pancreatic cancer (9,20,21). Activation (22) or upregulation 
(23) of pro-uPA may underlie the pro-tumor effects caused by 
these serine proteases. In the present study, we investigated 
the effects of the exogenous expression of polyserase-1 in 
pancreas-derived tumor cells (24,25). Collectively, our data 
suggest that polyserase-1 exerts pro-tumor effects through a 
mechanism involving activation of pro-uPA and phosphoryla-
tion of ERK.
Materials and methods
Cell lines and culture conditions. The cell line PANC-1 was 
purchased from Cell Lines Service and the SK-PC-3 cell line 
was kindly provided by Dr Francisco Real (National Cancer 
Research Centre, Madrid, Spain). Cells were routinely main-
tained at 37˚C in 5% CO2 in Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS).
Transfection and western blot analysis. The cell lines were 
transfected with the plasmid pcDNA3-FLAG-poly1, which 
contains the complete sequence of polyserase-1 and a FLAG 
epitope at the amino terminal region (17). Cells transfected 
with an empty pcDNA3 vector were employed as a control. 
Transfections were performed using the Lipofectamine system 
(Invitrogen) following the manufacturer's recommendations. 
Cells were selected in the presence of G-418 (Sigma-Aldrich) 
at 400 µg/ml. For western blot analysis, the proteins were 
separated on SDS/PAGE, and blotted onto PVDF membranes. 
Detection of exogenous polyserase-1 was performed using 
and an anti-FLAG antibody (Sigma Aldrich), and the H-140 
antibody from Santa Cruz Biotechnology was used to detect 
uPA. Antibodies to detect p-ERK and ERK were from Cell 
Signalling Technology.
qRT-PCR. Total RNA from cell cultures was obtained 
using the RNeasy Mini kit (Qiagen) following the manu-
facturer's recommendations. For cDNA synthesis, 2 µg of 
RNA was used as a template and the system ThermoScript 
RT-PCR (Invitrogen) was employed following the protocol 
recommended by the manufacturer. cDNA was then used 
as a template for quantitative PCR using TaqMan probe 
HS00917112_m1, TaqMan Master Mix reagent and the 
detection system 7300 Real-Time PCR system (Applied 
Biosystems). Expression of human β-actin was employed as 
endogenous control. Data analysis was performed using the 
computer program ABI PRISM 7900HT, and RQ Manager 
1.2 (Applied Biosystems).
Cell invasion assay. In vitro invasion potential was evaluated 
using 24-well Matrigel-coated invasion chambers with a 8-µm 
pore size (BD Biosciences). Cells (6x104) were allowed to 
migrate for 24 h using 10% FBS as a chemoattractant. Cells 
that reached the lower surface were fixed and stained with 
crystal violet. Three independent experiments were performed 
with triplicates for each condition. Cells were counted in eight 
randomly selected microscopic fields.
Soft agar colony formation. Anchorage-independent growth 
was examined using CytoSelect™ 96-Well In Vitro Tumor 
Sensitivity Assay kit (Cell Biolabs) following the manufac-
turer's instructions. Cell density was 6x103 cells/ml, and assays 
were performed for 8 days at 37˚C and 5% CO2 using 24-well 
Ultra-low attachment plates (Costar). Colonies were examined 
and photographed with a Leica microscope EZ 2.0 (Leica 
Microsystems).
Cell adhesion assay. The adhesion capacity of the different cell 
lines was analyzed using a colorimetric ECM Cell Adhesion 
Array kit (EMD Biosciences) following the manufacturer's 
instructions. Briefly, 2x105 cells were incubated for 2 h. The 
cells were then lysed, and the absorbance was measured at 
485 nm using a Synergy H4 Hybrid reader. All data are the 
mean of three independent experiments.
Statistical analysis. Statistical analysis was performed using 
the GraphPad Prism 5.0 software. Data are represented as 
means ± SE. The occurrence of significant differences was 
determined with the Student's-Welch t-test. P-values <0.05 
were considered to indicate statistically significant differences.
Results 
Exogenous expression of TMPRSS9/polyserase-1 in pancre-
atic cancer cells. To examine whether polyserase-1 affects the 
tumorigenic phenotype of pancreatic cancer cells, we employed 
two cell lines, PANC-1 and SK-PC-3, to perform further func-
tional analysis. These cell lines do not endogenously express 
TMPRSS9 as assessed by qRT-PCR; therefore, cells were 
transfected using the full-length cDNA for polyserase-1 (17) 
(Fig. 1A). Expression of exogenous polyserase-1 was assessed 
using qRT-PCR and western blot analysis by detection of the 
FLAG epitope at the amino-terminal region of the recombi-
nant protein (Fig. 1A). Cells that stably expressed TMPRSS9, 
referred to as PANC-1/TMPRSS9 and SK-PC-3/TMPRSS9, 
respectively, were chosen for further evaluation of potential 
phenotypic changes. PANC-1 and SK-PC-3 cells transfected 
with an empty vector, PANC-1c and SK-PC-3c, respectively, 
did not show immunoreactivity for the antibodies against 
FLAG epitope and were used as negative controls.
Polyserase-1 increases invasive properties of pancreatic 
cancer cells. Invasive capacity of the PANC-1/TMPRSS9 and 
SK-PC-3/TMPRSS9 cells was examined using Matrigel-coated 
invasion chambers (Fig. 1B). Average cell numbers penetrating 
the Matrigel per field were 312 in the case of PANC-1/TMPRSS9 
cells and 62 in the case of SK-PC-3/TMPRSS9 cells. However, 
only 102 PANC-1c and 10 SK-PC-3c invasive cells per field 
were observed in this assay (Fig. 1B). These data indicated that 
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the presence of polyserase-1 markedly increases the invasive 
capacity of both PANC-1 and SK-PC-3 cells.
Polyserase-1 enhances anchorage-independent growth of 
PANC-1 cells. Results obtained from invasive assays prompted 
us to perform new cell-based assays using PANC-1, a cell line 
commonly employed as an in vitro model of pancreatic cancer 
for tumorigenicity studies since its invasive and proliferative 
phenotypes have been widely characterized (24). Thus, we 
carried out a soft-agar colony formation assay to compare 
the PANC-1/TMPRSS9 and PANC-1c cells and, as shown in 
Fig. 2A, the colonies formed by cells expressing polyserase-1 
were more numerous (14 vs. 9) and much larger (82 µm vs. 
30 µm in diameter) than those formed by the PANC-1c cells 
after 8 days of growth (Fig. 2B). These data are also consis-
tent with the hypothesis that polyserase-1 acts a pro-tumor 
protease.
Presence of polyserase-1 activates pro-uPA and increases 
phosphorylation levels of ERK. Different mechanisms have 
been proposed to underlie the pro-tumor properties associ-
ated with the activities of TTSPs, including activation of 
pro-uPA or modulation of the ERK signaling pathway (23). We 
examined whether exogenous polyserase-1 also affects these 
mechanisms in PANC-1 cells. Toward this end, we performed 
Figure 1. Selection of PANC-1 and SK-PC-3 stable transfectants and invasion assay. (A) Left: western blot analysis of PANC-1 and SK-PC-3 cells expressing 
exogenous polyserase-1/TMPRSS9, indicated as PANC-1/TMPRSS9 and SK-PC-3/TMPRSS9, respectively. PANC-1c and SK-PC-3c indicate the control cells, 
transfected with an empty vector. The molecular weight marker is indicated on the left. Actin was used as a loading control. Right: qRT-PCR for mRNA expres-
sion levels of TMPRSS9 in the indicated cells. (B) Cell invasion assay using Matrigel-coated invasion chambers. Left: representative microscopic images of the 
indicated cells. Scale bar, 50 µm. Right: cells that reached the lower surface were counted, and the numbers are graphically represented. *p<0.05.
Figure 2. Polyserase-1/TMPRSS9 increases anchorage-independent growth 
of PANC-1 cells. (A) Representative microscopic images of colonies formed 
by PANC-1c and PANC-1/TMPRSS9 cells. Scale bar, 50 µm. (B) Graphical 
representation of the number and diameter of the colonies. *p<0.05, ***p<0.005.
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western blot analysis that revealed a significant activation of 
pro-uPA and high levels of phosphorylated ERK (p-ERK) in 
the PANC-1/TMPRSS9 but not in the PANC-1c cells (Fig. 3). 
These results suggest that TMPRSS9 may contribute to induce 
cancer cell invasion by enhancing the activation of survival 
pathways in tumor cells.
Polyserase-1 alters the adhesive properties of PANC-1 cells. 
To evaluate whether polyserase-1 alters adhesion of PANC-1 
cells to different ECM substrates, we performed a fluoro-
metric assay using PANC-1/TMPRSS9 and PANC-1c cells. 
The results clearly indicated that the presence of polyserase-1 
reduced the capacity of PANC-1 cells to bind to collagens as 
well as to vitronectin, and completely abolished adherence to 
laminin (Fig. 4). However, polyserase-1 did not alter the binding 
capacity of PANC-1 cells to fibronectin. Overall, these results 
indicated that polyserase-1 induced changes in cell adhesion 
which eventually leads to increased tumor progression.
Discussion
Proteolytic enzymes have been traditionally associated with 
tumor progression. In fact, proteases produced by cancer 
cells contribute not only to destroy the ECM barrier but also 
to actively release growth factors to control cell survival. 
However, recently, a growing number of proteases have also 
been associated with tumor-protective functions (26). One 
future challenge includes the identification of the precise 
functions of the proteolytic enzymes related to tumorigenesis. 
In this regard, we evaluated the potential contribution of 
polyserase-1/TMPRSS9 to tumorigenesis employing cell-
based assays. This unique enzyme belongs to the TTSP 
family of membrane-anchored serine proteases and is widely 
distributed in human and mouse tissues, yet its functional 
relevance is largely unknown (18). Polyserase-1 possesses 
three serine-protease domains in tandem each of which shows 
a high degree of identity with other members of the TTSP 
family, particularly with those belonging to the matriptase 
subfamily (17). Different TTSPs such as TMPRSS4, initially 
referred to as TMPRSS3 (20) and matriptase (21) have been 
shown to display pro-tumor activity in various types of 
tumors, including pancreatic carcinoma, one of the most 
aggressive cancers. In the present study, we demonstrated that 
polyserase-1 also acts as a pro-tumor protease. Thus, the pres-
ence of this enzyme increased the invasive properties of both 
SK-PC-3 and PANC-1 pancreatic cancer cells using Matrigel-
coated invasion chambers. Moreover, different reports have 
illustrated the usefulness of PANC-1 to examine the effect of 
the overexpression (27) or downregulation (28) of particular 
genes on anchorage-independent growth, a hallmark of malig-
nant transformation. Using similar approaches, we also found 
that the presence of polyserase-1 considerably enhanced this 
effect in PANC-1 cells.
Serase-1B, a spliced variant of polyserase-1 containing 
one serine protease domain, is able to activate pro-uPA (18), a 
serine protease largely involved in tumor progression. PANC-1 
cells expressing polyserase-1 were also found to exhibit 
significant pro-uPA activation when compared to PANC-1 
control cells. Furthermore, the presence of polyserase-1 also 
increased levels of ERK phosphorylation in this cell line. 
Similar effects have been previously associated to pro-tumor 
TTPSs. For example, TMPRSS4 upregulates uPA expression 
and activation in the DU145 prostate cancer and the NCI-H322 
lung cancer cell lines by a mechanism involving modulation 
of the ERK signaling pathway (23). Matriptase is also able 
to activate pro-UPA in the ovarian cancer cell line HRA (29) 
and the monocytic leukemia cell line THP-1 (22). On the 
other hand, induction of invasive and migratory capacities of 
PANC-1 cells has been linked to activation of ERK by phos-
phorylation (30). Collectively, our data suggest that TMPRSS9 
exerts pro-tumor effects on PANC-1 cancer cells overcoming 
apoptotic signals induced in anchorage-dependent cells when 
detaching from the surrounding ECM.
ECM components also affect the adhesive properties of 
tumor cells. In the case of PANC-1 cells, adhesion capacity to 
type I, II and IV collagens, laminin, fibronectin and vitronectin 
Figure 3. Western blot analysis showing pro-uPA activation and levels 
of phosphorylated ERK (p-ERK) and total ERK (ERK) in PANC-1c and 
PANC-1/TMPRSS9 cells. Molecular weight markers are indicated on the 
left. Actin was used as a loading control.
Figure 4. Presence of polyserase-1/TMPRSS9 modifies the adhesion profile 
of PANC-1 cells to different ECM components. Col I, type I collagen; Col II, 
type II collagen; Col IV, type IV collagen; FN, fibronectin; LN, laminin; VN, 
vitronectin. *p<0.05, **p<0.01.
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has been previously assessed (24). Our data indicated that 
polyserase-1 reduces the adhesion capacity of PANC-1 cells to 
collagens, laminin and vitronectin which may contribute to the 
promotion of cell migration and invasion (31). In reference to 
other TTSPs, overexpression of matriptase and TMPRSS4 was 
also found to alter the adhesion profile of tumor cells to ECM 
components thereby contributing to facilitate their invasive 
and metastatic properties (32,33).
In summary, in the present study, we provide initial 
evidence suggesting that polyserase-1 induces pro-tumor 
activities in pancreatic cancer cells and that uPA and ERK 
may participate in these processes. Consequently, polyserase-1 
may be involved in tumor progression, and inhibition of its 
activity could contribute to prevent progression of this malig-
nant tumor. Further exhaustive in vivo functional studies 
will help to shed light on the participation of polyserase-1 
in tumorigenesis. In this regard, generation of mice lacking 
TMPRSS9 may be a useful tool to understand the precise role 
of this polyserase-1 not only in pancreatic carcinoma but also 
in tumors from different origins. 
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